Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)

Bowtell, 2010, The genesis and evolution of high-grade serous ovarian cancer, Nat Rev Cancer, 10, 803, 10.1038/nrc2946 Cooke, 201112121169, Evolution of platinum resistance in high-grade serous ovarian cancer, Lancet Oncol, 10.1016/S1470-2045(11)70123-1 Barrett, 2008, Does body mass index affect progression-free or overall survival in patients with ovarian cancer?, Results from SCOTROC I trial, Ann Oncol, 19, 898 Pavelka, 2006, Effect of obesity on survival in epithelial ovarian cancer, Cancer, 107, 1520, 10.1002/cncr.22194 Matthews, 2009, The effect of obesity on survival in patients with ovarian cancer, Gynecol Oncol, 112, 389, 10.1016/j.ygyno.2008.10.016 Suh, 2012, Body mass index and survival in patients with epithelial ovarian cancer, J Obstet Gynaecol Res, 38, 70, 10.1111/j.1447-0756.2011.01628.x Backes, 2011, The impact of body weight on ovarian cancer outcomes, Int J Gynecol Cancer, 21, 1601, 10.1097/IGC.0b013e31822d2aa3 2013 Protani, 2012, Obesity and ovarian cancer survival: a systematic review and meta-analysis, Cancer Prev Res (Phila), 5, 901, 10.1158/1940-6207.CAPR-12-0048 Lyman, 2003, Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices, J Clin Oncol, 21, 4524, 10.1200/JCO.2003.05.002 Griggs, 2005, Undertreatment of obese women receiving breast cancer chemotherapy, Arch Intern Med, 165, 1267, 10.1001/archinte.165.11.1267 Field, 2008, Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey, J Oncol Pract, 4, 108, 10.1200/JOP.0832001 Bonadonna, 1995, Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up, N Engl J Med, 332, 901, 10.1056/NEJM199504063321401 Rosner, 1996, Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541, J Clin Oncol, 14, 3000, 10.1200/JCO.1996.14.11.3000 Colleoni, 2005, Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index, Lancet, 366, 1108, 10.1016/S0140-6736(05)67110-3 Lyman, 2009, Impact of chemotherapy dose intensity on cancer patient outcomes, J Natl Compr Cancer Netw, 7, 99, 10.6004/jnccn.2009.0009 Jordan, 2008, Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis, Int J Cancer, 122, 1598, 10.1002/ijc.23287 Calvert, 1989, Carboplatin dosage: prospective evaluation of a simple formula based on renal function, J Clin Oncol, 7, 1748, 10.1200/JCO.1989.7.11.1748 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 Du Bois, 1989, A formula to estimate the approximate surface area if height and weight be known. 1916, Nutrition, 5, 303 Griggs, 2012, Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 30, 1553, 10.1200/JCO.2011.39.9436 Collins, 2011, Carboplatin dosing in ovarian cancer: problems and pitfalls, Int J Gynecol Cancer, 21, 1213 Nelson, 2012, An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers, J Oncol Pharm Pract, 18, 323, 10.1177/1078155211435714 Lepage, 1993, Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte), Ann Oncol, 4, 651, 10.1093/oxfordjournals.annonc.a058619 Fauci, 2011, Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer, Gynecol Oncol, 122, 532, 10.1016/j.ygyno.2011.05.023 Nagel, 2012, Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer, Gynecol Oncol, 124, 221, 10.1016/j.ygyno.2011.10.003 Lee, 2011, Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer, Br J Cancer, 105, 360, 10.1038/bjc.2011.256 Hourdequin, 2013, Larson RJ, Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis, Ann Oncol, 24, 2952 Abu Saadeh, 20131701214, Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival, Eur J Obstet Gynecol Reprod Biol Califano, 2014229153, High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer, J Cell Physiol Diaz, 2013, Obesity-associated adipokines correlate with survival in epithelial ovarian cancer, Gynecol Oncol, 129, 353, 10.1016/j.ygyno.2013.02.006